Oncolytics Biotech (ONCY) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing pelareorep, an intravenously delivered immunotherapeutic targeting RAS-mutated tumors and enhancing immune response against cancer.

• Pelareorep is a proprietary reovirus isolate designed to improve tumor microenvironment and increase patient response to various oncology treatments, including chemotherapies and immunotherapies.

• Recently completed a two-step redomestication, now incorporated in Nevada as of March 31, 2026.

Financial performance and metrics

• The registration statement incorporates by reference the Annual Report on Form 10-K for the year ended December 31, 2025, and recent Current Reports on Form 8-K.

• The most recent audit report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement for each offering.